Login Register Cart 0
Generic placeholder image

Cardiovascular & Hematological Disorders-Drug Targets

Editor-in-Chief

ISSN (Print): 1871-529X
ISSN (Online): 2212-4063

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Two-way Road of Kidney and Hypercalcemia: A Narrative Review

Author(s): Ziba Aghsaeifard and Reza Alizadeh*

Volume 22, Issue 4, 2022

Published on: 23 December, 2022

Page: [200 - 206] Pages: 7

DOI: 10.2174/1871529X23666221205143041

Price: $65

Abstract

Calcium homeostasis is regulated by the dyad of parathyroid hormone and calcitriol, whereas kidney, intestine, and bone are the primary target sites. Elevation of serum calcium levels and hypercalcemia are likely markers of pathological conditions, particularly malignancy and hyperparathyroidism. Similarly, several dysfunctions within the body can direct hypercalcemia. Furthermore, chemicals and drugs can also drive this condition. Owing to the significant role of the kidney in calcium homeostasis, renal abnormalities lead to hypercalcemia and increased calcium levels can have pathological effects on the kidney. This review is designed to highlight some of the commonly known causes of hypercalcemia and their effects on the kidney.

« Previous Next »
Graphical Abstract

[1]
Mirrakhimov Hypercalcemia of malignancy: An update on pathogenesis and management. N. Am. J. Med. Sci., 2015, 7(11), 483-493.
[http://dx.doi.org/10.4103/1947-2714.170600] [PMID: 26713296]
[2]
AlZahrani; Sinnert; Gernsheimer Acute kidney injury, sodium disorders, and hypercalcemia in the aging kidney: diagnostic and therapeutic management strategies in emergency medicine. Clin. Geriatr. Med., 2013, 29(1), 275-319.
[http://dx.doi.org/10.1016/j.cger.2012.10.007] [PMID: 23177611]
[3]
Clines Mechanisms and treatment of hypercalcemia of malignancy. Curr. Opin. Endocrinol. Diabetes Obes., 2011, 18(6), 339-346.
[http://dx.doi.org/10.1097/MED.0b013e32834b4401] [PMID: 21897221]
[4]
Felsenfeld; Levine; Rodriguez Pathophysiology of calcium, phosphorus, and magnesium dysregulation in chronic kidney disease. Semin. Dial., 2015, 28(6), 564-577.
[http://dx.doi.org/10.1111/sdi.12411] [PMID: 26303319]
[5]
Figueres; Linglart; Bienaime; Allain-Launay; Roussey-Kessler; Ryckewaert; Kottler; Hourmant Kidney function and influence of sunlight exposure in patients with impaired 24-hydroxylation of vitamin D due to CYP24A1 mutations. Am. J. Kidney Dis., 2015, 65(1), 122-126.
[http://dx.doi.org/10.1053/j.ajkd.2014.06.037] [PMID: 25446019]
[6]
Khaleel; Wu; Wong; Hsu; Chou; Chen A single nucleotide polymorphism (rs4236480) in TRPV5 calcium channel gene is associated with stone multiplicity in calcium nephrolithiasis patients. Mediators Inflamm., 2015, 2015, 375427.
[http://dx.doi.org/10.1155/2015/375427] [PMID: 26089600]
[7]
Vezzoli; Scillitani; Corbetta; Terranegra; Dogliotti; Guarnieri; Arcidiacono; Macrina; Mingione; Brasacchio; Eller-Vainicher; Cusi; Spada; Cole; Hendy; Spotti; Soldati Risk of nephrolithiasis in primary hyperparathyroidism is associated with two polymorphisms of the calcium-sensing receptor gene. J. Nephrol., 2015, 28(1), 67-72.
[http://dx.doi.org/10.1007/s40620-014-0106-8] [PMID: 24832896]
[8]
Guha; Bankura; Ghosh; Pattanayak; Ghosh; Pal Polymorphisms in CaSR and CLDN14 genes associated with increased risk of kidney stone disease in patients from the eastern part of India. PLoS One, 2015, 10(6), e0130790.
[9]
Vargas-Poussou; Mansour-Hendili; Baron; Bertocchio; Travers; Simian; Treard; Baudouin; Beltran; Broux; Camard; Cloarec; Cormier; Debussche; Dubosclard; Eid; Haymann; Kiando; Kuhn; Lefort; Linglart; Lucas-Pouliquen; Macher; Maruani; Ouzounian; Polak; Requeda; Robier; Silve; Souberbielle; Tack; Vezzosi; Jeunemaitre; Houillier Familial hypocalciuric hypercalcemia types 1 and 3 and primary hyperparathyroidism: Similarities and differences. J. Clin. Endocrinol. Metab., 2016, 101(5), 2185-2195.
[http://dx.doi.org/10.1210/jc.2015-3442] [PMID: 26963950]
[10]
Mastromatteo; Lamacchia; Campo; Conserva; Baorda; Cinque; Guarnieri; Scillitani; Cignarelli A novel mutation in calcium-sensing receptor gene associated to hypercalcemia and hypercalciuria. BMC Endocr. Disord., 2014, 14(1), 81.
[http://dx.doi.org/10.1186/1472-6823-14-81] [PMID: 25292184]
[11]
Muirhead; Zaltman; Gill; Churchill; Poulin-Costello; Mann; Cole Hypercalcemia in renal transplant patients: prevalence and management in Canadian transplant practice. Clin. Transplant., 2014, 28(2), 161-165.
[http://dx.doi.org/10.1111/ctr.12291] [PMID: 24329899]
[12]
Evenepoel; Cooper; Holdaas; Messa; Mourad; Olgaard; Rutkowski; Schaefer; Deng; Torregrosa; Wuthrich; Yue A randomized study evaluating cinacalcet to treat hypercalcemia in renal transplant recipients with persistent hyperparathyroidism. Am. J. Transplant., 2014, 14(11), 2545-2555.
[http://dx.doi.org/10.1111/ajt.12911] [PMID: 25225081]
[13]
Jo; Han; So; Jun; Han Effect of cinacalcet in kidney transplant patients with hyperparathyroidism. Transplant. Proc., 2019, 51(5), 1397-1401.
[http://dx.doi.org/10.1016/j.transproceed.2019.01.141] [PMID: 31155177]
[14]
O’Callaghan; Yau Treatment of malignancy-associated hypercalcemia with cinacalcet: A paradigm shift. Endocr. Connect., 2021, 10(1), R13-R24.
[http://dx.doi.org/10.1530/EC-20-0487] [PMID: 33289687]
[15]
Tzotzas; Goropoulos; Karras; Terzaki; Siolos; Doumas; Zaramboukas; Tigas Effective long-term management of parathyromatosis-related refractory hypercalcemia with a combination of denosumab and cinacalcet treatment. Hormones (Athens), 2022, 21(1), 171-176.
[http://dx.doi.org/10.1007/s42000-021-00343-w] [PMID: 34993886]
[16]
Aghsaeifard; Alizadeh Clinical post-transplant lymphoproliferative disorders. Cardiovascular & Hematological Disorders-Drug Targets, 2022, 22(2), 96-103.
[17]
Aghsaeifard; Ghafarzadeh; Alizadeh Pregnancy and sex hormone changes after kidney transplant. Clin. Invest. Ginecol. Obstet., 2023, 50(1), 100812.
[http://dx.doi.org/10.1016/j.gine.2022.100812]
[18]
Cruzado; Moreno; Torregrosa; Taco; Mast; Gómez-Vaquero; Polo; Revuelta; Francos; Torras; García-Barrasa; Bestard; Grinyó A randomized study comparing parathyroidectomy with cinacalcet for treating hypercalcemia in kidney allograft recipients with hyperparathyroidism. J. Am. Soc. Nephrol., 2016, 27(8), 2487-2494.
[http://dx.doi.org/10.1681/ASN.2015060622] [PMID: 26647424]
[19]
Nanmoku; Shinzato; Kubo; Shimizu; Yagisawa Effects of denosumab on hypercalcemia and bone mineral density loss in kidney transplant recipients. Clin. Nephrol., 2019, 92(1), 1-8.
[http://dx.doi.org/10.5414/CN109723] [PMID: 30990412]
[20]
Aghsaeifard; Alizadeh; Bagheri Association between neutrophil gelatinase-associated lipocalin (NGAL) and iron profile in chronic renal disease. Arch. Physiol. Biochem., 2022, 128(3), 703-707.
[http://dx.doi.org/10.1080/13813455.2020.1720742] [PMID: 31994917]
[21]
van den Broek; Chang; Elliott; Jepson Chronic kidney disease in cats and the risk of total hypercalcemia. J. Vet. Intern. Med., 2017, 31(2), 465-475.
[http://dx.doi.org/10.1111/jvim.14643] [PMID: 28190275]
[22]
Ketteler; Block; Evenepoel; Fukagawa; Herzog; McCann; Moe; Shroff; Tonelli; Toussaint; Vervloet; Leonard Executive summary of the 2017 KDIGO chronic kidney disease–mineral and bone disorder (CKD-MBD) guideline update: what’s changed and why it matters. Kidney Int., 2017, 92(1), 26-36.
[http://dx.doi.org/10.1016/j.kint.2017.04.006] [PMID: 28646995]
[23]
Peng; Li; Zhang; Chen; Su; Smith; Dong Hyperglycemia, p53, and mitochondrial pathway of apoptosis are involved in the susceptibility of diabetic models to ischemic acute kidney injury. Kidney Int., 2015, 87(1), 137-150.
[http://dx.doi.org/10.1038/ki.2014.226] [PMID: 24963915]
[24]
Araujo; Araujo; Kubrusly; Duarte; Araujo; Oliveira; Daher; Silva Resolution of hypercalcemia and acute kidney injury after treatment for pulmonary tuberculosis without the use of corticosteroids. Am. J. Trop. Med. Hyg., 2013, 88(3), 592-595.
[http://dx.doi.org/10.4269/ajtmh.11-0768] [PMID: 23339205]
[25]
Horino; Ichii; Terada A rare presentation of hypermagnesemia associated with acute kidney injury due to hypercalcemia. Intern. Med., 2019, 58(8), 1123-1126.
[http://dx.doi.org/10.2169/internalmedicine.1927-18] [PMID: 30568149]
[26]
Hanna; Kaldas; Arman; Wang; Hammer; Sinkowitz; Rastogi Hypercalcemia-induced acute kidney injury in a Caucasian female due to radiographically silent systemic sarcoidosis. Clin. Nephrol. Case Stud., 2018, 6(1), 21-26.
[http://dx.doi.org/10.5414/CNCS109513] [PMID: 30206511]
[27]
Sorensen Calcium intake and urinary stone disease. Transl. Androl. Urol., 2014, 3(3), 235-240.
[PMID: 26816771]
[28]
Letavernier; Daudon; Vitamin hypercalciuria and kidney stones. Nutrients, 2018, 10(3), 366.
[http://dx.doi.org/10.3390/nu10030366] [PMID: 29562593]
[29]
Luyckx; Tuttle; Garcia-Garcia; Gharbi; Heerspink; Johnson Reducing major risk factors for chronic kidney disease. Kidney Int Suppl, 2017, 7(2), 71-87.
[http://dx.doi.org/10.1016/j.kisu.2017.07.003]
[30]
Arroyo; Fenves; Emmett The calcium-alkali syndrome. Proc. Bayl. Univ. Med. Cent., 2013, 26(2), 179-181.
[http://dx.doi.org/10.1080/08998280.2013.11928954] [PMID: 23543983]
[31]
Stojceva-Taneva; Taneva; Selim Hypercalcemia as a cause of kidney failure: Case report. Open Access Maced. J. Med. Sci., 2016, 4(2), 283-286.
[http://dx.doi.org/10.3889/oamjms.2016.044] [PMID: 27335601]
[32]
Hosomi; Hirabe; Tokuda; Nakamura; Amano; Okamoto Calcium effects and systemic exposure of vitamin D3 analogues after topical treatment of active vitamin D3 -containing ointments in rats. Eur. J. Pharmacol., 2016, 788, 98-103.
[http://dx.doi.org/10.1016/j.ejphar.2016.06.028] [PMID: 27321871]
[33]
Cusano; Thys-Jacobs; Bilezikian Hypercalcemia Due to Vitamin D Toxicity.Vitamin D, 4th ed.; Feldman, , Ed.; Academic Press, 2018, pp. 507-526.
[http://dx.doi.org/10.1016/B978-0-12-809963-6.00082-1]
[34]
Aihara; Yamada; Oka; Kamimura; Nakano; Tsuruya; Harada Hypercalcemia and acute kidney injury induced by eldecalcitol in patients with osteoporosis: a case series of 32 patients at a single facility. Ren. Fail., 2019, 41(1), 88-97.
[http://dx.doi.org/10.1080/0886022X.2019.1578667] [PMID: 30909788]
[35]
Guerra; Vieira Neto; Laurindo; Paula; Moysés Neto Hypercalcemia and renal function impairment associated with vitamin D toxicity: Case report. J. Bras. Nefrol., 2016, 38(4), 466-469.
[http://dx.doi.org/10.5935/0101-2800.20160074] [PMID: 28001186]
[36]
Jeong; Bae Hypercalcemia associated with acute kidney injury and metabolic alkalosis. Electrolyte Blood Press., 2010, 8(2), 92-94.
[http://dx.doi.org/10.5049/EBP.2010.8.2.92] [PMID: 21468203]
[37]
Koc; Hoser; Akdag; Kendir; Ersoy Treatment of secondary hyperparathyroidism with paricalcitol in patients with end-stage renal disease undergoing hemodialysis in Turkey: An observational study. Int. Urol. Nephrol., 2019, 51(7), 1261-1270.
[http://dx.doi.org/10.1007/s11255-019-02175-5] [PMID: 31161518]
[38]
Aloia; Katumuluwa; Stolberg; Usera; Mikhail; Hoofnagle; Islam Safety of calcium and vitamin D supplements, a randomized controlled trial. Clin. Endocrinol. (Oxf.), 2018, 89(6), 742-749.
[http://dx.doi.org/10.1111/cen.13848] [PMID: 30180273]
[39]
Velez; Donnelly-Strozzo; Stanik-Hutt Simplifying the complexity of primary hyperparathyroidism. J. Nurse Pract., 2016, 12(5), 346-352.
[http://dx.doi.org/10.1016/j.nurpra.2015.12.017]
[40]
Verdelli; Corbetta Mechanisms in endocrinology: Kidney involvement in patients with primary hyperparathyroidism: An update on clinical and molecular aspects. 2017, 176(1) R39
[41]
van der Plas; Engelsman; Özyilmaz; van der Horst-Schrivers; Meijer; van Dam; Pol; de Borst; Kruijff Impact of the introduction of calcimimetics on timing of parathyroidectomy in secondary and tertiary hyperparathyroidism. Ann. Surg. Oncol., 2017, 24(1), 15-22.
[http://dx.doi.org/10.1245/s10434-016-5450-6] [PMID: 27459979]
[42]
Messa; Alfieri Secondary and Tertiary Hyperparathy roidism Front. Horm. Res. Basel, Karger, 2019, 51, 91-108.
[43]
Galindo; Romao; Valsamis; Weinerman; Harris Hypercalcemia of malignancy and colorectal cancer. World J. Oncol., 2016, 7(1), 5-12.
[http://dx.doi.org/10.14740/wjon953w] [PMID: 26998187]
[44]
Shupp; Kolb; Mukhopadhyay; Bussard Cancer metastases to bone: Concepts, mechanisms, and interactions with bone osteoblasts. Cancers (Basel), 2018, 10(6), 182.
[http://dx.doi.org/10.3390/cancers10060182] [PMID: 29867053]
[45]
Žofková, I. Hypercalcemia. Pathophysiological Aspects. Physiol. Res., 2016, 65(1), 1-10.
[http://dx.doi.org/10.33549/physiolres.933059] [PMID: 26596315]
[46]
Meehan; Udumyan; Kardell; Landén; Järhult, J.; Wallin, G. Lithium-associated hypercalcemia: Pathophysiology, prevalence, management. World J. Surg., 2018, 42(2), 415-424.
[http://dx.doi.org/10.1007/s00268-017-4328-5] [PMID: 29260296]
[47]
Griebeler; Kearns; Ryu; Thapa; Hathcock; Melton, III; Wermers Thiazide-associated hypercalcemia: Incidence and association with primary hyperparathyroidism over two decades. J. Clin. Endocrinol. Metab., 2016, 101(3), 1166-1173.
[http://dx.doi.org/10.1210/jc.2015-3964] [PMID: 26751196]
[48]
Yoon; Kim; Lee; Jeong; Shim; Han; Choi; Shin; Ahn Adrenal insufficiency presenting as hypercalcemia and acute kidney injury. Int. Med. Case Rep. J., 2016, 9, 223-226.
[http://dx.doi.org/10.2147/IMCRJ.S109840] [PMID: 27536162]
[49]
Yamada; Arase; Morishita; Tsuchimoto; Torisu; Torisu; Tsuruya; Nakano; Kitazono Adrenal crisis presented as acute onset of hypercalcemia and hyponatremia triggered by acute pyelonephritis in a patient with partial hypopituitarism and pre-dialysis chronic kidney disease. CEN Case Rep., 2019, 8(2), 83-88.
[http://dx.doi.org/10.1007/s13730-018-0371-9] [PMID: 30456557]
[50]
Graziani; Calvetta; Cucchiari; Valaperta; Montanelli Life-threatening hypercalcemia in patients with rhabdomyolysis-induced oliguric acute renal failure. J. Nephrol., 2011, 24(1), 128-131.
[http://dx.doi.org/10.5301/JN.2010.5794] [PMID: 20954138]
[51]
Sadjadi; Sadjadi Severe hypercalcemia complicating recovery of acute kidney injury due to rhabdomyolysis. Am. J. Case Rep., 2014, 15, 393-396.
[http://dx.doi.org/10.12659/AJCR.891046] [PMID: 25218143]
[52]
Pal; Khan; China; Mittal; porwal; Shrivastava; Taneja; Hossain; Mandalapu; Gayen; Wahajuddin; Sharma; Trivedi; Sanyal; Bhadauria; Godbole; Gupta; Chattopadhyay Theophylline, a methylxanthine drug induces osteopenia and alters calciotropic hormones, and prophylactic vitamin D treatment protects against these changes in rats. Toxicol. Appl. Pharmacol., 2016, 295, 12-25.
[http://dx.doi.org/10.1016/j.taap.2016.02.002] [PMID: 26851681]
[53]
Nampoothiri; Fernández-Rebollo; Yesodharan; Gardella; Rush; Langman; Jüppner Jansen metaphyseal chondrodysplasia due to heterozygous H223R-PTH1R mutations with or without overt hypercalcemia. J. Clin. Endocrinol. Metab., 2016, 101(11), 4283-4289.
[http://dx.doi.org/10.1210/jc.2016-2054] [PMID: 27410178]
[54]
Shimomura-Kuroki; Farooq; Sekimoto; Amizuka; Shimomura Characterization of a PTH1R missense mutation responsible for Jansen type metaphyseal chondrodysplasia. Odontology, 2017, 105(2), 150-154.
[http://dx.doi.org/10.1007/s10266-016-0247-4] [PMID: 27160269]
[55]
Stokes; Nielsen; Hannan; Thakker Hypercalcemic disorders in children. J. Bone Miner. Res., 2017, 32(11), 2157-2170.
[http://dx.doi.org/10.1002/jbmr.3296] [PMID: 28914984]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy